Iovance Biotherapeutics (IOVA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.11
- Estimate
- -$0.13
- Surprise
- +18.4%
- Revenue (period 2026-06-30)
- $99.3M
- Score at report (before → after)
- 5.4 → 6.5/10
Revenue source: xbrl.
How the report landed
Iovance Biotherapeutics (IOVA) reported a narrower loss than forecast — diluted EPS of -$0.11 against the -$0.13 estimate (a 18.4% beat on a still-unprofitable quarter). TrendMatrix's engine moved from Sell (5.4/10) to Buy (Wait) at 6.5/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates IOVA Sell at 5.4/10.
2 of the last 4 quarters beat the estimate; this quarter's +18.4% surprise compares with a -1.1% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Pipeline: TILVANCE-301 (Amtagvi confirmatory Phase 3)
- Target reached (-11.9% upside)
- Quality below floor (3.1 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $10.00
- Price target
- $11.35
- Stop
- $9.18
- Upside to target
- +13.5%
Risk check: RSI 75 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.
IOVA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $4.24B
- P/E (fwd)
- -32.6
- 52-week range
- $1.76–$9.41
- Off 52-week high
- -6.3%
- RSI (14)
- 75
- Volume vs avg
- 1.32×
- Score today
- 5.4/10